Physician profile
Lorena D Narvaez
NPI 1376685651
$6,799.16
in general payments reported to CMS, 2019-2025
22 companies · $3,585 in 2025
The $3,585 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $442 · 2023: $750 · 2024: $1,771 · 2025: $3,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,022 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,021.95 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,134.23 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $995.31 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $590.71 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $519.73 | 2024-2025 | |
| Lilly USA, LLC | $482.39 | 2024-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $438.15 | 2023-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $408.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.98 | 2024-2025 | Xifaxan, Relistor, Plenvu |
| Gilead Sciences, INC. | $333.71 | 2023-2025 | Epclusa, Livdelzi |
| Phathom Pharmaceuticals, INC. | $295.05 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $245.31 | 2023-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $195.16 | 2022-2023 | Stelara |
| Regeneron Healthcare Solutions, INC. | $171.58 | 2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $158.57 | 2024-2025 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $123.17 | 2023 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $107.60 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $77.83 | 2025 | Iqirvo |
| Novo Nordisk INC | $44.27 | 2025 | Wegovy |
| Pfizer INC. | $33.56 | 2025 | |
| Inspire Medical Systems, INC. | $19.44 | 2025 | Inspire |
| Ironwood Pharmaceuticals, INC | $15.13 | 2024 | |
| Redhill Biopharma INC. | $14.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorena Narvaez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.